Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares

Key Points

• Maze Therapeutics CMO Harold Bernstein sold 16,141 shares at an average price of $26.93, totaling approximately $434,677. The transaction, conducted under a Rule 10b5-1 plan, reduced his direct holdings by 50% to 16,141 shares.
• MAZE shares fell 0.8% to $26.43, with the stock trading well below its 52-week high of $53.65. The company reported a quarterly loss of $0.76 per share, in line with analyst expectations.
• Analysts remain broadly optimistic, with a consensus “Buy” rating and an average price target of $63.40, while institutional investors including Frazier Life Sciences Management and Braidwell increased or initiated positions.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 16,141 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares of the company's stock, valued at approximately $434,677.13. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, September 4th, Harold Bernstein sold 9,705 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10.
• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total value of $445,680.62.

Maze Therapeutics Trading Down 0.8%

NASDAQ MAZE traded down $0.22 during trading hours on Friday, reaching $26.43. The company's stock had a trading volume of 633,043 shares, compared to its average volume of 665,641. The firm has a fifty day simple moving average of $27.00 and a 200-day simple moving average of $28.23. The stock has a market cap of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. Maze Therapeutics, Inc. has a 52 week low of $21.95 and a 52 week high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.76). Equities analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MAZE. Squarepoint Ops LLC boosted its stake in Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company's stock worth $580,000 after acquiring an additional 5,822 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. AXQ Capital LP boosted its position in shares of Maze Therapeutics by 114.1% during the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company's stock worth $453,000 after purchasing an additional 8,098 shares in the last quarter. Braidwell LP acquired a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company's stock valued at $529,000 after buying an additional 17,312 shares in the last quarter.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday, September 24th. Citigroup began coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a "buy" rating and a $50.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, BTIG Research reiterated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $63.40.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.